Simplify Asset Management Inc. Purchases Shares of 53,510 Vor Biopharma Inc. $VOR

Simplify Asset Management Inc. purchased a new position in Vor Biopharma Inc. (NASDAQ:VOR) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 53,510 shares of the company’s stock, valued at approximately $955,000.

A number of other large investors have also modified their holdings of the stock. RA Capital Management L.P. raised its stake in shares of Vor Biopharma by 172.7% in the fourth quarter. RA Capital Management L.P. now owns 5,404,998 shares of the company’s stock valued at $70,697,000 after acquiring an additional 3,422,697 shares in the last quarter. Fcpm Iii Services B.V. grew its stake in Vor Biopharma by 852.8% during the 4th quarter. Fcpm Iii Services B.V. now owns 3,617,354 shares of the company’s stock worth $47,315,000 after purchasing an additional 3,237,714 shares in the last quarter. Frazier Life Sciences Management L.P. acquired a new position in Vor Biopharma during the 4th quarter worth $33,275,000. Paradigm Biocapital Advisors LP purchased a new stake in Vor Biopharma during the 4th quarter worth about $22,890,000. Finally, NEXTBio Capital Management LP purchased a new stake in Vor Biopharma during the 4th quarter worth about $13,080,000. Hedge funds and other institutional investors own 97.29% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on VOR. HC Wainwright reaffirmed a “buy” rating and issued a $31.00 price target on shares of Vor Biopharma in a research report on Monday, May 18th. Jefferies Financial Group raised Vor Biopharma to a “strong-buy” rating in a research report on Thursday, April 30th. Wedbush upped their target price on shares of Vor Biopharma from $15.00 to $18.00 and gave the stock a “neutral” rating in a research note on Thursday, May 14th. Wall Street Zen cut shares of Vor Biopharma from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Finally, Weiss Ratings upgraded shares of Vor Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $42.25.

Vor Biopharma Price Performance

NASDAQ:VOR opened at $20.59 on Friday. The stock has a 50-day simple moving average of $15.15 and a 200-day simple moving average of $14.66. Vor Biopharma Inc. has a 1 year low of $6.50 and a 1 year high of $65.80.

Vor Biopharma (NASDAQ:VOR) last issued its earnings results on Monday, March 30th. The company reported $307.61 earnings per share for the quarter. On average, equities analysts expect that Vor Biopharma Inc. will post -2.51 earnings per share for the current year.

Insider Transactions at Vor Biopharma

In related news, Director Ra Capital Management, L.P. sold 589,257 shares of the company’s stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $16.59, for a total value of $9,775,773.63. Following the completion of the transaction, the director directly owned 4,555,741 shares of the company’s stock, valued at $75,579,743.19. This represents a 11.45% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders sold 2,742,903 shares of company stock valued at $44,672,376 over the last three months. Corporate insiders own 0.27% of the company’s stock.

About Vor Biopharma

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).